By Sheeba M. | May 23, 2026
MSO Debt Crunch: Refinancing Window Closing as Rates Hold Steady
The cannabis MSO debt story nobody’s watching is happening in the bond markets right now. While Wall Street obsesses over quarterly earnings beats, a much quieter—and more dangerous—reckoning is unfolding in the debt refinancing space.
The Refinancing Cliff
According to filing data from the last six months, Curaleaf, Trulieve, and Cresco Labs collectively have $2.8B in debt maturing between July 2026 and December 2026. This is not a gradual roll; it’s a cliff. And the credit market environment has shifted.
Cannabis debt was trading at 12-14% yields six months ago. Today, that’s compressed to 9-10% for investment-grade MSOs, but refinancing terms have tightened dramatically. Lenders are now demanding:
- Higher leverage covenants: Maximum EBITDA multiples dropping from 5.5x to 4.75x
- Tighter interest coverage thresholds: Minimum 2.5x (was 3.0x)
- Revenue maintenance floors: New restrictions on state license abandonments
For Trulieve, this means refinancing its $1.1B tranche means accepting terms that limit M&A capacity through 2027. For Cresco, it means tighter cash deployment restrictions.
Why This Matters for Equity Investors
Green Thumb Industries refinanced early in April at 8.5% and locked in 5-year terms. That move now looks prescient. The companies waiting until Q3 will pay 50-100 basis points more. On $1B+ debt, that’s an extra $5-10M annual cash drain.
The real risk: if any MSO misses EBITDA targets in Q2 or Q3, refinancing becomes a crisis event. We’ve already seen Verano tighten guidance. A similar move from Curaleaf or Trulieve transforms refinancing from routine to distressed.
Sources
- SEC EDGAR — Cannabis Company Filings — Debt schedules and covenant details
- Credit Markets Research — Yield and refinancing analysis
Track cannabis stocks with the Weedstock Real-Time Tracker